Quellen:

1
Hoch E, Friemel CM, Schneider M, Herausgeber. Cannabis: Potenzial und Risiko: Eine wissenschaftliche Bestandsaufnahme [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 2019 [zitiert 9. September 2024]. Verfügbar unter:http://link.springer.com/10.1007/978-3-662-57291-7

2
Hauser W, Petzke F. Evidenz der Wirksamkeit und Sicherheit von Cannabispraparaten bei chronischen Schmerzen: Ein methodisches Minenfeld. Bundesgesundheitsbl. Juli 2019; 62(7):836–44.

3
Hoch E, Friemel CM, Schneider M, Herausgeber. Cannabis: Potenzial und Risiko: Eine wissenschaftliche Bestandsaufnahme [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 2019 [zitiert 9. September 2024]. Verfügbar unter:http://link.springer.com/10.1007/978-3-662-57291-7

4
Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, u. a. Cannabinoidsfor treatment of spasticity and other symptoms related to multiple sclerosis(CAMS study): multicentre randomised placebo-controlled trial. The Lancet.November 2003;362(9395):1517–26.

5
Longoria V, Parcel H, Toma B, Minhas A, Zeine R. Neurological Benefits,Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: ASystematic Review of Cannabinoid Effects in Multiple Sclerosis and ExperimentalModels of Demyelination. Biomedicines. 24. Februar 2022;10(3):539.

6
Cuttler C, Spradlin A, Cleveland MJ, Craft RM. Short- and Long-Term Effects ofCannabis on Headache and Migraine. The Journal of Pain. Mai 2020;21(5–6):722–30.

7
Ghorayeb I. Cannabis for Restless Legs Syndrome. In: Monti JM, Pandi-PerumalSR, Murillo-Rodriguez E, Herausgeber. Cannabinoids and Sleep. Cham: Springer International Publishing; 2021 [zitiert 9. September2024]. S. 173–81. (Advances in ExperimentalMedicine and Biology; Bd. 1297). Verfügbar unter: https://link.springer.com/10.1007/978-3-030-61663-2_13

8
ZajicekJ, Fox P, Sanders H, Wright D, Vickery J, Nunn A, u. a. Cannabinoids fortreatment of spasticity and other symptoms related to multiple sclerosis (CAMSstudy): multicentre randomised placebo-controlled trial. The Lancet. November 2003;362(9395):1517–26.

9
Longoria V, Parcel H, Toma B, Minhas A, Zeine R. Neurological Benefits,Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: ASystematic Review of Cannabinoid Effects in Multiple Sclerosis and ExperimentalModels of Demyelination. Biomedicines. 24. Februar 2022;10(3):539.

10
Oreja-Guevara C. [Treatment of spasticity in multiple sclerosis: newperspectives regarding the use of cannabinoids]. Rev Neurol. 1. Oktober2012;55(7):421–30.

11
Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. Oktober 2015;12(4):825–36.

12
Skelley JW, Deas CM, Curren Z, Ennis J. Use of cannabidiol in anxiety andanxiety-related disorders. Journal of the American Pharmacists Association.Januar 2020;60(1):253–61.

13
Greer GR, Grob CS, Halberstadt AL. PTSD Symptom Reports of Patients Evaluated for the New Mexico MedicalCannabis Program. Journal of Psychoactive Drugs. Januar 2014;46(1):73–7.

14
Denson TF, Earleywine M. Decreased depression in marijuana users. AddictiveBehaviors. April 2006;31(4):738–42.

15
Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P. Cannabinoids inattention-deficit/hyperactivity disorder: A randomised-controlled trial.European Neuropsychopharmacology. August 2017;27(8):795–808.

16
Loflin M, Earleywine M, De Leo J, Hobkirk A. Subtypes of AttentionDeficit-Hyperactivity Disorder (ADHD) and Cannabis Use. Substance Use &Misuse. 21. Marz 2014;49(4):427–34.

17
Thaler A, Arad S, Schleider LBL, Knaani J, Taichman T, Giladi N, u. a. Singlecenter experience with medical cannabis in Gilles de la Tourette syndrome.Parkinsonism & Related Disorders. April 2019;61:211–3.

18
Muller-Vahl K, Schneider U, Koblenz A, Jobges M, Kolbe H, Daldrup T, u. a.Treatment of Tourette’s Syndrome with Δ9-Tetrahydrocannabinol (THC): A Randomized Crossover Trial. Pharmacopsychiatry.12. April 2002;35(02):57–61.

19
Walsh JH, Maddison KJ, Rankin T, Murray K, McArdle N, Ree MJ, u. a. Treatinginsomnia symptoms with medicinal cannabis: a randomized, crossover trial of theefficacy of a cannabinoid medicine compared with placebo. SLEEP. 12. November 2021;44(11):zsab149.

20
Walsh JH, Maddison KJ, Rankin T, Murray K, McArdle N, Ree MJ, u. a. Treatinginsomnia symptoms with medicinal cannabis: a randomized, crossover trial of theefficacy of a cannabinoid medicine compared with placebo. SLEEP. 12. November 2021;44(11):zsab149.

21
Kafil TS, Nguyen TM, MacDonald JK, Chande N. Cannabis for the treatment ofulcerative colitis. Cochrane IBD Group, Herausgeber. Cochrane Database ofSystematic Reviews [Internet]. 8. November 2018 [zitiert 9. September2024];2019(6). Verfügbar unter:http://doi.wiley.com/10.1002/14651858.CD012954.pub2

22
Kafil TS, Nguyen TM, MacDonald JK, Chande N. Cannabis for the Treatment ofCrohn’s Disease and Ulcerative Colitis:Evidence From Cochrane Reviews. 4. Marz 2020;

23
Naftali T, Bar-Lev Schleider L, Almog S, Meiri D, Konikoff FM. Oral CBD-richCannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn’s Disease, a Randomised Controlled Trial.Journal of Crohn’s and Colitis. 8. November 2021;15(11):1799–806.

24
Fitzcharles M, Ste-Marie PA, Hauser W, Clauw DJ, Jamal S, Karsh J, u. a.Efficacy, Tolerability, and Safety of CannabinoidTreatments in the RheumaticDiseases: A Systematic Review of Randomized Controlled Trials. Arthritis Care& Research. Mai 2016;68(5):681–8.

25
Jadoon KA, Tan GD, O’Sullivan SE. A single dose of cannabidiol reduces bloodpressure in healthy volunteers in a randomized crossover study. JCI Insight. 15. Juni 2017;2(12):e93760.

26
THC : CBD for Hidradenitis Suppurativa / Acne Inversa [Internet]. Verfugbarunter: https://cannakeys.com/thc-cbd-for-hidradenitis-suppurativa-acne-inversa/

27
Grotenhermen F, Olah A. Case in Context: Acne Inversa (HidradenitisSuppurativa). Cannabis and Cannabinoid Research. 1. August 2023;8(4):608–11.

28
Derakhshan N, Kazemi M. Cannabis for Refractory Psoriasis—High Hopes for a Novel Treatment and aLiterature Review. CCP. 1. August 2016;11(2):146–7.

29
Wroński A, Jarocka-Karpowicz I, Stasiewicz A, Skrzydlewska E. Phytocannabinoidsin the Pharmacotherapy of Psoriasis. Molecules. 25. Januar2023;28(3):1192.

30
Shao K, Stewart C, Grant-Kels JM. Cannabis and the skin. Clinics in Dermatology. September 2021;39(5):784–95.

31
Kaemmerer T, Clanner-Engelshofen BM, Lesmeister T, French LE, Reinholz M.Cannabinoids in hyperhidrosis. Journal of Dermatological Treatment. 31.Dezember 2023;34(1):2127308.

32
Mosaed S, Gavin Herbert Eye Institute, University of California, Irvine, CA,USA, Irvine School of Medicine, University of California, Irvine, CA, USA, LiuJH, Viterbi Family Department of Ophthalmology, University of California, SanDiego, CA, USA, Minckler DS, u. a. The Effect of Inhaled Cannabis onIntraocular Pressure in Healthy Adult Subjects. Ophthalmology. 2021;15(1):33.

33
Silvestro, S., Mammana, S., Cavalli, E., Bramanti, P., & Mazzon, E. (2019). Use of cannabidiol in the treatment of epilepsy: Efficacy and security in clinical trials.Molecules, 24(8), 1459.